# Genetic characterization of Lynch syndrome germline variants in a LATAM cohort using a customized NGS gene panel

**Authors:** Cecilia Mathó, Santiago Chávez, Rafael Sebastián Fort, Adriana Della Valle, Florencia Neffa, José Roberto Sotelo-Silveira, Nora Artagaveytia, María Ana Duhagon

PMC · DOI: 10.3389/fonc.2025.1589765 · Frontiers in Oncology · 2025-08-01

## TL;DR

This study identifies new Lynch syndrome gene variants in a Uruguayan colorectal cancer cohort using a custom NGS panel, showing its effectiveness for in-house genetic testing.

## Contribution

The study introduces a customized NGS panel for Lynch syndrome screening in a Latin American population and identifies four novel pathogenic variants.

## Key findings

- Pathogenic or likely pathogenic variants were found in 25 out of 70 patients.
- Four novel Lynch syndrome-associated variants were identified.
- The custom NGS panel proved effective for scalable in-house testing despite minor coverage limitations.

## Abstract

Lynch Syndrome accounts for 1–7% of all colorectal cancers and is caused by germline mutations in DNA mismatch repair (MMR) genes. Timely molecular diagnosis is crucial for effective genetic counseling and management. Among understudied Latin American populations, Uruguay’s genetic admixture provides an opportunity to identify novel Lynch Syndrome related variants.

This study analyzed 70 unrelated Uruguayan colorectal cancer patients meeting Lynch Syndrome clinical criteria to identify carriers of pathogenic variants. A customized Next-Generation Sequencing (NGS) panel was developed and sequenced on the Ion Torrent platform to analyze nine genes: MLH1, MSH2, MSH6, EPCAM, FAN1, MUTYH, PMS1, PMS2, and APC. Copy number variations and large EPCAM deletions are not detected by the assay. Gene variants were prioritized based on allelic frequency, in silico predictions, pathogenicity records, and ACMG guidelines. The performance of this custom NGS panel was evaluated for in-house applications, and its limitations were thoroughly assessed.

The custom NGS panel demonstrated effectiveness for scalable in-house testing despite minor disclosed sequence coverage limitations. Pathogenic and likely pathogenic variants were identified in 25 patients, including four novel Lynch Syndrome-associated variants. In four patients, a rare ambiguously classified gene variant co-occurs with a known pathogenic variant in another gene. The mutation profile correlated with clinical parameters such as age of diagnosis, diagnosis criteria, tumor location, and microsatellite instability (MSI).

This is the most comprehensive genetic study to date on a Uruguayan Lynch syndrome cohort. The mutational landscape aligns with findings in other populations while highlighting novel variants of clinical relevance. These findings highlight the value of customized panels for improving genetic screening in small-scale healthcare facilities.

## Linked entities

- **Genes:** MLH1 (mutL homolog 1) [NCBI Gene 4292], MSH2 (mutS homolog 2) [NCBI Gene 4436], MSH6 (mutS homolog 6) [NCBI Gene 2956], EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072], FAN1 (FANCD2 and FANCI associated nuclease 1) [NCBI Gene 22909], MUTYH (mutY DNA glycosylase) [NCBI Gene 4595], PMS1 (PMS1 homolog 1, mismatch repair system component) [NCBI Gene 5378], PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395], APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324]
- **Diseases:** colorectal cancer (MONDO:0005575), Lynch Syndrome (MONDO:0005835)

## Full-text entities

- **Genes:** MLH1 (mutL homolog 1) [NCBI Gene 4292] {aka COCA2, FCC2, HNPCC, HNPCC2, LYNCH2, MLH-1}, EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}, PMS1 (PMS1 homolog 1, mismatch repair system component) [NCBI Gene 5378] {aka HNPCC3, MLH2, PMSL1, hPMS1}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, MUTYH (mutY DNA glycosylase) [NCBI Gene 4595] {aka MYH}, FAN1 (FANCD2 and FANCI associated nuclease 1) [NCBI Gene 22909] {aka KIAA1018, KMIN, MTMR15, hFAN1}, MSH6 (mutS homolog 6) [NCBI Gene 2956] {aka GTBP, GTMBP, HNPCC5, HSAP, LYNCH5, MMRCS3}, PMS2 (PMS1 homolog 2, mismatch repair system component) [NCBI Gene 5395] {aka HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMSL2}
- **Diseases:** Lynch Syndrome (MESH:D003123), colorectal cancer (MESH:D015179), tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12353692/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12353692/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12353692/full.md

---
Source: https://tomesphere.com/paper/PMC12353692